Nobelpharma Signs License Agreement for ProBioGen’s Vaccine Manufacturing Platform

On August 12, 2021, German contract development and manufacturing organization (CDMO) ProBioGen announced that Japanese pharmaceutical company Nobelpharma had signed a license agreement to use ProBioGen’s vaccine manufacturing platform AGE1.CR.plX to develop Nobelpharma’s lead vaccine.

The appeal of the manufacturing platform is that it is designed as a true cell suspension line. Because it grows in a chemically defined medium, it is free of any adventitious agents. Consequently, cultivation can be done in large bioreactors, resulting in reduced lead times and a more controlled production process in closed systems.

Established in 2003, Nobelpharma has developed 18 new drugs and one new medical product with a focus on products for underserved patient populations. AGE.CR.plX will be used in the development of their viral vaccine.

"Cell-based systems for vaccine production offer a cost-effective, efficient and flexible alternative to traditional vaccine production,” said Gabriele Schneider, chief business officer at ProBioGen, in a company press release. “With the AGE1.CR.pIX, we have created an exceptionally robust and scalable system, which is becoming increasingly important and we are pleased about the increased demand."

Source: ProBioGen